Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

These highlights do not include all the information needed to use BETOPTIC S safely and effectively. See full prescribing information for BETOPTIC S. BETOPTIC S Ophthalmic Suspension 0.25% as base, sterile topical ophthalmic drops Initial U.S. Approval: 1985

×

Overview

What is These highlights do not include all the information needed to use BETOPTIC S safely and effectively. See full prescribing information for BETOPTIC S. BETOPTIC S Ophthalmic Suspension 0.25% as base, sterile topical ophthalmic drops Initial U.S. Approval: 1985?

BETOPTIC S Ophthalmic Suspension 0.25% contains betaxolol hydrochloride, a cardioselective beta-adrenergic receptor inhibitor, in a sterile resin suspension formulation. Betaxolol hydrochloride is a white, crystalline powder, with a molecular weight of 343.89. The chemical structure is presented below.

Empirical Formula: CHNO•HCl Chemical Name:(±)-1-[p-[2-(cyclopropylmethoxy) ethyl]phenoxy]-3-(isopropylamino)-2-propanol hydrochloride.

Each mL of BETOPTIC S Ophthalmic Suspension 0.25% contains: betaxolol HCl 2.8 mg equivalent to 2.5 mg of betaxolol base. benzalkonium chloride 0.01%. mannitol, poly (styrene-divinyl benzene) sulfonic acid, carbomer 934P, edetate disodium, hydrochloric acid or sodium hydroxide (to adjust pH) and purified water.

BETOPTIC S Ophthalmic Suspension 0.25% has pH of approximately 7.6 and an osmolality of approximately 290 mOsmol/kg.



What does These highlights do not include all the information needed to use BETOPTIC S safely and effectively. See full prescribing information for BETOPTIC S. BETOPTIC S Ophthalmic Suspension 0.25% as base, sterile topical ophthalmic drops Initial U.S. Approval: 1985 look like?



What are the available doses of These highlights do not include all the information needed to use BETOPTIC S safely and effectively. See full prescribing information for BETOPTIC S. BETOPTIC S Ophthalmic Suspension 0.25% as base, sterile topical ophthalmic drops Initial U.S. Approval: 1985?

Bottle filled with 10 and 15 mL of 0.25% sterile ophthalmic suspension

What should I talk to my health care provider before I take These highlights do not include all the information needed to use BETOPTIC S safely and effectively. See full prescribing information for BETOPTIC S. BETOPTIC S Ophthalmic Suspension 0.25% as base, sterile topical ophthalmic drops Initial U.S. Approval: 1985?

How should I use These highlights do not include all the information needed to use BETOPTIC S safely and effectively. See full prescribing information for BETOPTIC S. BETOPTIC S Ophthalmic Suspension 0.25% as base, sterile topical ophthalmic drops Initial U.S. Approval: 1985?

BETOPTIC S Ophthalmic Suspension 0.25% is indicated for the treatment of elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension.

Instill one drop of BETOPTIC S Ophthalmic Suspension 0.25% in the affected eye(s) twice daily. BETOPTIC S may be used alone or in combination with other IOP lowering medications.


What interacts with These highlights do not include all the information needed to use BETOPTIC S safely and effectively. See full prescribing information for BETOPTIC S. BETOPTIC S Ophthalmic Suspension 0.25% as base, sterile topical ophthalmic drops Initial U.S. Approval: 1985?

Sorry No Records found


What are the warnings of These highlights do not include all the information needed to use BETOPTIC S safely and effectively. See full prescribing information for BETOPTIC S. BETOPTIC S Ophthalmic Suspension 0.25% as base, sterile topical ophthalmic drops Initial U.S. Approval: 1985?

Sorry No Records found


What are the precautions of These highlights do not include all the information needed to use BETOPTIC S safely and effectively. See full prescribing information for BETOPTIC S. BETOPTIC S Ophthalmic Suspension 0.25% as base, sterile topical ophthalmic drops Initial U.S. Approval: 1985?

Sorry No Records found


What are the side effects of These highlights do not include all the information needed to use BETOPTIC S safely and effectively. See full prescribing information for BETOPTIC S. BETOPTIC S Ophthalmic Suspension 0.25% as base, sterile topical ophthalmic drops Initial U.S. Approval: 1985?

Sorry No records found


What should I look out for while using These highlights do not include all the information needed to use BETOPTIC S safely and effectively. See full prescribing information for BETOPTIC S. BETOPTIC S Ophthalmic Suspension 0.25% as base, sterile topical ophthalmic drops Initial U.S. Approval: 1985?

BETOPTIC S Ophthalmic Suspension 0.25% is contraindicated in patients with:


What might happen if I take too much These highlights do not include all the information needed to use BETOPTIC S safely and effectively. See full prescribing information for BETOPTIC S. BETOPTIC S Ophthalmic Suspension 0.25% as base, sterile topical ophthalmic drops Initial U.S. Approval: 1985?

No information is available on overdosage in humans. The oral LD of the drug ranged from 350 - 920 mg/kg in mice and 860 - 1050 mg/kg in rats. The symptoms which might be expected with an overdose of a systemically administered beta-adrenergic receptor inhibitor are bradycardia, hypotension, bronchospasm and acute cardiac failure.

A topical overdose of BETOPTIC S Ophthalmic Suspension 0.25% may be flushed from the eye(s) with warm tap water.  If overdose occurs, treatment should be symptomatic and supportive.


How should I store and handle These highlights do not include all the information needed to use BETOPTIC S safely and effectively. See full prescribing information for BETOPTIC S. BETOPTIC S Ophthalmic Suspension 0.25% as base, sterile topical ophthalmic drops Initial U.S. Approval: 1985?

Storage and HandlingStore at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) (see USP Controlled Room Temperature).Storage and HandlingStore at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) (see USP Controlled Room Temperature).BETOPTIC S Ophthalmic Suspension 0.25% is supplied as follows: 10 and 15 mL in plastic ophthalmic DROP-TAINER dispensers. Tamper evidence is provided with a shrink band around the closure and neck area of the DROP-TAINER package.10 mL 0065-0246-1015 mL 0065-0246-15Storage and Handling BETOPTIC S Ophthalmic Suspension 0.25% is supplied as follows: 10 and 15 mL in plastic ophthalmic DROP-TAINER dispensers. Tamper evidence is provided with a shrink band around the closure and neck area of the DROP-TAINER package.10 mL 0065-0246-1015 mL 0065-0246-15Storage and Handling BETOPTIC S Ophthalmic Suspension 0.25% is supplied as follows: 10 and 15 mL in plastic ophthalmic DROP-TAINER dispensers. Tamper evidence is provided with a shrink band around the closure and neck area of the DROP-TAINER package.10 mL 0065-0246-1015 mL 0065-0246-15Storage and Handling


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Betaxolol HCl, a cardioselective (beta-1-adrenergic) receptor inhibitor, does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Orally administered beta-adrenergic receptor inhibitors reduce cardiac output in healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor antagonists may inhibit the sympathetic stimulatory effect necessary to maintain adequate cardiac function.

When instilled in the eye, BETOPTIC S Ophthalmic Suspension 0.25% has the action of reducing elevated IOP, whether or not accompanied by glaucoma. Ophthalmic betaxolol has minimal effect on pulmonary and cardiovascular parameters.

Elevated IOP presents a major risk factor in glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. Betaxolol has the action of reducing elevated as well as normal IOP and the mechanism of ocular hypotensive action appears to be a reduction of aqueous production as demonstrated by tonography and aqueous fluorophotometry.

Non-Clinical Toxicology
BETOPTIC S Ophthalmic Suspension 0.25% is contraindicated in patients with:











































































































Drug/Laboratory Test Interactions

Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening.

Amphetamines may interfere with urinary steroid determinations.

Carcinogenesis/Mutagenesis –

As with many topically applied ophthalmic drugs, this drug is absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic receptor inhibitors may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and death due to cardiac failure, have been reported with topical application of beta-adrenergic receptor inhibitors.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).